This shows that in metabolic diseases such as atherosclerosis, the downstream signaling pathway of FGF21 is disrupted and a state of FGF21 resistance appears, leading to an increase in the concentration of FGF21 to compensate. This evidence concerns the gene FGF21 and metabolic disease.